BCL-2 Inhibitor Program
Oncology
PreclinicalResearch
Key Facts
About Vincerx Pharma
Vincerx Pharma is a NASDAQ-listed biotech (VINC) with a mission to address high unmet needs in oncology by developing novel therapeutics. The company employs a capital-efficient, virtual R&D model to in-license and advance a pipeline of targeted and immuno-oncology candidates. Its strategy centers on precise asset selection, biomarker-driven development, and exploring combination regimens to overcome therapeutic resistance. Despite facing significant financial and operational challenges common to early-stage biotechs, Vincerx aims to create value through disciplined pipeline progression and strategic partnerships.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Bendamustine Intermediate | AR Life Science | Commercial |